Evidence map›Paper›PMID 34693882›Full record

ArticlemAbs

Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice.

Bhupal Ban, Rodell C Barrientos, Therese Oertel, Essie Komla, Connor Whalen, Megan Sopko, Yingjian You, Partha Banerjee, Agnieszka Sulima, Arthur E Jacobson and 3 more

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs.The Journal of pharmacology and experimental therapeutics · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Bhupal BanPharmaceutical Center, Indiana Biosciences Research Institute, Indianapolis, Indiana, United States.
Rodell C BarrientosLaboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States.
Therese OertelLaboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States.
Essie KomlaLaboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States.
Connor WhalenLaboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States.
Megan SopkoPharmaceutical Center, Indiana Biosciences Research Institute, Indianapolis, Indiana, United States.
Yingjian YouPharmaceutical Center, Indiana Biosciences Research Institute, Indianapolis, Indiana, United States.
Partha BanerjeePharmaceutical Center, Indiana Biosciences Research Institute, Indianapolis, Indiana, United States.
Agnieszka SulimaDepartment of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, United States.
Arthur E JacobsonDepartment of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, United States.
Kenner C RiceDepartment of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, United States.
Gary R MatyasLaboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States.ORCID 0000-0002-2074-2373
Vidadi YusibovPharmaceutical Center, Indiana Biosciences Research Institute, Indianapolis, Indiana, United States.
Indiana Biosciences Research Institute · USNational Institute on Drug Abuse · USWalter Reed Army Institute of Research · USHenry M. Jackson Foundation · US

Funding

INTERACT Meeting with FDA on Cohort Design and Development of ALFQ as an Adjuvant for Heroin VaccineUG3DA048351 · NIDA · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI MATYAS, GARY R. · 2018 to 2019
$8.2M
Development of a Practical Heroin-HIV VaccineDP1DA034787 · NIDA · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI MATYAS, GARY R. · 2012 to 2016
$7.2M
NIDA NIH HHS DP1 DA034787NIDA NIH HHS UG3 DA048351
6 · The paper itself

Abstract

The prevalence and societal impact of opioid use disorder (OUD) is an acknowledged public health crisis that is further aggravated by the current pandemic. One of the devastating consequences of OUD is opioid overdose deaths. While multiple medications are now available to treat OUD, given the prevalence and societal burden, additional well-tolerated and effective therapies are still needed. To this point, we have developed chimeric monoclonal antibodies (mAb) that will specifically complex with fentanyl and its analogs in the periphery, thereby preventing them from reaching the central nervous system. Additionally, mAb-based passive immunotherapy offers a high degree of specificity to drugs of abuse and does not interfere with an individual's ability to use any of the medications used to treat OUD. We hypothesized that sequestering fentanyl and its analogs in the periphery will mitigate their negative effects on the brain and peripheral organs. This study is the first report of chimeric mAb against fentanyl and its analogs. We have discovered, engineered the chimeric versions, and identified the selectivity of these antibodies, through

Indexed as

Antineoplastic Agents, ImmunologicalOpioid-Related DisordersAnimalsAntibodies, MonoclonalFentanylMiceTissue DistributionAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalFentanylfentanyl analogsFentanyl mAbopioidsopioid use disorderpassive immunization

Identifiers

PMID34693882
PMCPMC8547829
OpenAlexW3210758715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.